Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Horizon Therapeutics (HZNP)

80.43   -0.77 (-0.95%) 01-21 00:34
Open: 82.17 Pre. Close: 81.2
High: 82.58 Low: 78.755
Volume: 4,268,906 Market Cap: 17,752M
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 82.772 - 83.18 83.18 - 83.511
Low: 77.648 - 78.19 78.19 - 78.63
Close: 79.664 - 80.492 80.492 - 81.164

Technical analysis

as of: 2021-01-20 4:48:25 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 96.45     One year: 112.66
Support: Support1: 72.59    Support2: 66.41
Resistance: Resistance1: 82.58    Resistance2: 96.45
Pivot: 76.62
Moving Average: MA(5): 79.27     MA(20): 74.57
MA(100): 75.07     MA(250): 57.31
MACD: MACD(12,26): 2.18     Signal(9): 1.54
Stochastic oscillator: %K(14,3): 85.55     %D(3): 83.46
RSI: RSI(14): 63.43
52-week: High: 86.67  Low: 23.81  Change(%): 116.7
Average Vol(K): 3-Month: 265331  10-Days: 191302

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
HZNP has closed below upper band by 22.3%. Bollinger Bands are 36.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 20 Jan 2021
Pharma Stock Horizon Therapeutics Eyes Buy Point As Earnings Growth Continues - Investor's Business Daily

Tue, 19 Jan 2021
Horizon Therapeutics Public Limited Company (HZNP) Soars 3.15% on January 19 -

Fri, 15 Jan 2021
Horizon Therapeutics Plc (HZNP) Chairman, President and CEO Timothy P Walbert Sold $16. ... - Yahoo Finance

Thu, 14 Jan 2021
Horizon Therapeutics Public Limited Company (HZNP) Soars 2.35% on January 14 -

Mon, 11 Jan 2021
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials - Yahoo Finance

Fri, 08 Jan 2021
Horizon Therapeutics Plc (HZNP) EVP & President, International Vikram Karnani Sold $2. ... - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 221
Shares Float (M) 218
% Held by Insiders 1.13
% Held by Institutions 90.90
Shares Short (K) 8,910
Shares Short P. Month (K) 6,300

Stock Financials

EPS 3.610
EPS Est This Year 1.070
EPS Est Next Year 1.250
Book Value (p.s.) 17.210
Profit Margin 43.55
Operating Margin 16.81
Return on Assets (ttm) 4.0
Return on Equity (ttm) 29.6
Qtrly Rev. Growth 89.7
Gross Profit (p.s.) 4.250
Sales Per Share 8.246
EBITDA (p.s.) 1.482
Qtrly Earnings Growth 1506.00
Operating Cash Flow (M) 337
Levered Free Cash Flow (M) 168

Stock Valuations

PE Ratio 22.28
PEG Ratio
Price to Book value 4.67
Price to Sales 9.75
Price to Cash Flow 52.64

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.